Triad Life Sciences completes A$25m funding round, anticipates ASX listing in coming months – Learn More >>
Triad Life Sciences® introduces InnovaMatrix™AC, a next-generation extracellular matrix (ECM) product that advances the science of the wound management, burn care, and surgical markets by combining the technological advantages of a medical device – reliability, reproducibility, and a rigorous safety profile – with the inherent, natural benefits found within the placenta.
Triad Life Sciences® is dedicated to increasing patient access to innovative, reliable, and accessible technologies that address complex surgical wounds, chronic stalled wounds, burns, and other regenerative dermal applications.
Next-Generation Wound Treatment
InnovaMatrix™ Platform is the only placental-derived medical device technology on the market to address the inherent challenges and related restrictions of Human Cells, Tissue, and Cellular and Tissue-Based Products (HCT/Ps). This patent-pending technology provides an array of regenerative medicine opportunities and is the foundation for Triad’s robust product development pipeline.
InnovaMatrix™ AC provides a reliable solution in medical device form where the current HCT/P placental technologies are fraught with substantial donor variability, thereby resulting in inconsistent products. Produced under the stringent requirements of Current Good Manufacturing Practice (CGMP) with a highly controlled source material, InnovaMatrix™ AC is a consistent and reproducible alternative for wound care management.
Triad’s mission is to provide safe, cost-effective wound care solutions to the market. To that end, Triad’s state-of-the-art, scalable manufacturing operation maximizes efficiency and creates economic benefits for the patients, healthcare providers, and payors.